Valeant as a Work in Progress for Markets, Investors

Timothy Chiang, senior pharmaceutical analyst at BTIG, examines second-quarter results from Valeant Pharmaceuticals and what the drugmaker needs to do to drive growth going forward. He speaks with Bloomberg's David Westin on "Bloomberg ‹GO›." Chiang, his family and firm, do not own shares of Valeant. (Source: Bloomberg)

Perella CEO Says No One Is Working on an IPO Prospectus
07:26 - Bob Steel, chief executive officer and partner at Perella Weinberg Partners, discusses the company’s approach to acquisitions and how long it may take to go public. He speaks with Bloomberg's Erik Schatzker on "Bloomberg Daybreak: Americas." (Source: Bloomberg)
  • Bridgewater Associates' Ray Dalio: Charlie Rose
  • UN General Assembly: Charlie Rose
  • Rolling Stone Sale a New Beginning, Says Mediatech's Bibb